Chemical industry – Page 93
-
Opinion
From lab to leader
Derek Lowe asks (with some trepidation): do drug companies need scientists at the top?
-
Business
Russian investment vehicle sets sights on innovative drugs
Rusnano hopes to make a killing by investing in new technologies in the pharmaceutical sector
-
Feature
Changing the rules of extraction
As the price of oil goes up, reserves previously uneconomical to exploit become attractive. Nuala Moran explores the chemical technology being used
-
Business
Court convicts ex-Aptuit researcher over drug data
Altered liquid chromatography results at Scottish site lead to first successful good lab practice prosecution
-
Business
AstraZeneca partners with Moderna for $240 million
Pharma company sheds more jobs and backs messenger RNA therapeutics
-
Business
Global AstraZeneca restructuring will cost 1600 jobs
Firm will focus drug development efforts in three strategic R&D centres in the UK, Sweden and the US
-
Business
Interpol teams up with pharma
Pharmaceutical crime programme will seek to reduce trade in fake drugs
-
Business
Dow makes $1.5bn divestiture plans
Liveris in favour of ‘selectively pruning’ further non-core units
-
Business
Dispute over Arkema finances
French speciality chemical company Arkema accused of misrepresenting business sold to investment firm last year
-
Opinion
New antibiotics: what's the hold up?
It’s more a research problem, than a commercial one, says Derek Lowe
-
Business
Alcohol dependence pill approved in EU
Selincro tablets from Lundbeck designed to reduce consumption of alcohol
-
Business
University to acquire Shell UK R&D site
Site at Thornton will become a science park under the stewardship of the University of Chester
-
Business
UK considers patent rule change for trials
Government to change law that organisations say makes the country less appealing as a location for clinical trials
-
Business
Dow rapped for $1bn tax scheme
Judge opines: ‘tax law deals in economic realities, not legal abstractions’
-
Business
Does chemical regulation boost innovation?
Report suggests that supply of innovation responds to extra demand created by new laws
-
Business
Talk of a $6.6bn deal for Elan
Potential offer from Royalty Pharma comes as Elan ponders how to spend its cash from Tysabri rights
-
Business
$595m octreotide deal grabs Roche
Company will get worldwide rights to oral formulation of growth hormone drug
-
Business
Merck resolves Vytorin case for $688m
Investors say the company knew about Enhance trial failure but withheld information
-
Business
BMS sells OTC drugs for $482m
Bristol-Myers Squibb will offload rights to a range of over-the-counter products to Reckitt Benckiser
-
Careers
Toxicologist with pesticides on the brain
Vanessa Fitsanakis’ career in toxicology goes all the way back to the farm where she grew up. Helen Carmichael traces her journey from agriculture to academia